Skip to main content
    K

    Kymera Therapeutics Inc (KYMR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $106.83
    +0.15 (+0.14%)

    Market Cap: $8.79B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(9/24)
    Avg Surprise
    -41.35%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.26
    Range$-1.47 - $-1.04
    20 analysts
    EPS Revisions
    2
    0
    7d
    2
    11
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.03-22.8%
    60d ago$-1.24-1.9%
    30d ago$-1.25-0.9%
    7d ago$-1.260.0%
    Current$-1.26
    Revenue Consensus
    $3M
    Range$-1000000 - $20M
    19 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.99
    Range$-1.44 - $-0.28
    20 analysts
    Revenue Consensus
    $61M
    Range$53M - $95M
    23 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.99---
    Sep 26EST
    		-$-1.26---
    Jun 26
    Reported Aug 5
    		$-0.62$-0.64+3.13%Beat+34.7%
    Mar 26
    Reported Apr 30
    		$-0.71$-0.86+17.44%Beat+13.4%
    Dec 25
    Reported Feb 26
    		$-0.97$-0.77-25.97%Miss-9.0%
    Sep 25
    Reported Nov 4
    		$-0.94$-0.78-20.51%Miss-14.6%
    Jun 25
    Reported Aug 11
    		$-0.95$-0.80-18.75%Miss-63.8%
    Mar 25
    Reported May 9
    		$-0.82$-0.91+9.89%Beat-32.3%
    Dec 24
    Reported Feb 27
    		$-0.89$-0.79-12.92%Miss-256.0%
    Sep 24
    Reported Oct 31
    		$-0.82$-0.84+2.38%Beat+8.9%
    Jun 24
    Reported Aug 7
    		$-0.58$-0.66+12.12%Beat+13.4%
    Mar 24
    Reported May 2
    		$-0.62$-0.72+13.89%Beat+11.4%
    Dec 23
    Reported Feb 22
    		$-0.25$-0.40+37.50%Beat+58.3%
    Sep 23
    Reported Nov 2
    		$-0.90$-0.70-28.57%Miss-13.9%
    Jun 23
    Reported Aug 3
    		$-0.67$-0.74+9.46%Beat+14.1%
    Mar 23
    Reported May 4
    		$-0.70$-0.69-1.45%Miss+1.4%
    Dec 22
    Reported Feb 23
    		$-0.60$-0.63+4.76%Beat+9.1%
    Sep 22
    Reported Nov 3
    		$-0.79$-0.75-5.33%Miss-41.1%
    Jun 22
    Reported Aug 9
    		$-0.78$-0.69-13.04%Miss-41.8%
    Mar 22
    Reported May 3
    		$-0.71$-0.67-5.97%Miss-144.8%
    Dec 21
    Reported Feb 24
    		$-0.66$-0.57-15.79%Miss-127.6%
    Sep 21
    Reported Nov 10
    		$-0.56$-0.37-51.35%Miss-43.6%
    Jun 21
    Reported Aug 6
    		$-0.55$-0.25-120.00%Miss-31.0%
    Mar 21
    Reported May 6
    		$-0.29$-0.20-45.00%Miss+69.8%
    Dec 20
    Reported Mar 11
    		$-0.29$-0.04-625.00%Miss-
    Sep 20
    Reported Nov 5
    		$-0.39N/A-113.40%Miss-
    Jun 20
    Reported Aug 21
    		$-0.42N/AN/ABeat-
    Mar 20
    Reported Jun 29
    		$-0.96$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-32.97EV/EBITDAN/A
    Price/FCF-44.08xFCF Yield-2.27%
    Profitability
    Profit Margin-285.30%Operating Margin-116.30%
    ROE-24.10%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio10.34xQuick Ratio10.34x
    Trading Statistics
    Beta1.98Avg Volume891.79K
    52-Week High$130.0552-Week Low$55.26

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$108.90
    SMA 20$112.12
    SMA 50$114.96
    SMA 200$94.07
    EMA 10$109.48
    EMA 20$111.21
    EMA 50$111.88
    EMA 200$95.21

    MACD

    Line: -2.01Signal: -1.69Hist: -0.32

    ADX

    ADX: 12.4+DI: 17.7-DI: 21.5

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down76.0
    PSAR$102.57

    Bollinger Bands

    Upper Band$121.05
    Lower Band$103.20
    %B Position1592%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    40.7

    Momentum Oscillators

    Stoch %K39.2
    Stoch %D42.7
    Williams %R-64.8
    ROC (10d)-4.4%
    Momentum-4.96
    CCI (20d)-98.8
    MFI (14d)49.9

    Volatility Measures

    ATR (14d)$5.29(5.0%)
    StdDev (20d)4.46
    Hist Vol40.1%(High)

    Volume Flow

    VWAP$106.86
    OBV32.3M
    AD Line10.6M
    CMF (20d)0.015

    Volume Metrics

    Avg Vol (20d)903.1K
    Vol Ratio1.1x
    VWMA (20d)$112.13

    Pivot Points

    R3$115.86
    R2$113.96
    R1$110.32
    Pivot Point$108.42
    S1$104.78
    S2$102.88
    S3$99.24

    Advanced Oscillators

    TSI-13.72
    Ultimate Osc53.1
    KST-71.49

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$65.00M$34.37M$2.87M$2.76M$11.48M$22.10M$7.39M$3.74M$25.65M$10.29M$47.88M$4.73M
    Cost of Revenue$0$0$-76,178,000$0$0$0$1.97M$0$0$0$865,000$0
    Gross Profit$65.00M$34.37M$2.87M$2.76M$11.48M$22.10M$7.39M$3.74M$25.65M$10.29M$47.88M$4.73M
    Operating Expenses$140.61M$118.52M$100.77M$95.28M$96.03M$96.53M$88.15M$75.86M$76.58M$68.12M$67.20M$62.24M
    R&D$119.48M$98.16M$83.83M$74.09M$78.39M$80.25M$71.82M$60.41M$59.20M$48.82M$52.97M$48.12M
    SG&A$21.13M$20.36M$16.93M$17.34M$17.64M$16.27M$16.33M$15.46M$17.37M$14.37M$14.23M$14.12M
    Operating Income$-75,607,000$-84,154,000$-97,895,000$-92,521,000$-84,557,000$-74,426,000$-80,755,000$-72,124,000$-50,925,000$-57,831,000$-19,312,000$-57,509,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-61,211,000$-69,234,000$-86,981,000$-82,175,000$-76,614,000$-65,581,000$-70,752,000$-62,487,000$-42,062,000$-48,557,000$-14,368,000$-52,867,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-61,211,000$-69,234,000$-86,981,000$-82,175,000$-76,614,000$-65,581,000$-70,752,000$-62,487,000$-42,062,000$-48,557,000$-14,368,000$-52,867,000
    EBITDA$-59,181,000$-67,212,000$-84,949,000$-80,026,000$-74,530,000$-63,533,000$-68,765,000$-60,500,000$-40,124,000$-47,096,000$-13,477,000$-51,972,000
    EBIT$-61,211,000$-69,234,000$-86,981,000$-82,175,000$-76,614,000$-65,581,000$-70,752,000$-62,487,000$-42,062,000$-48,557,000$-14,368,000$-52,867,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KYMR

    News

    Raymond James sets USD 140 target for Kymera Therapeutics stock

    Raymond James initiated coverage on Kymera Therapeutics (KYMR) with an Outperform rating and a USD 140.00 price target. This follows Citi's recent increase of its target to USD 150.00...

    ad-hoc-news.de•10/15/26•Bullish

    Raymond James set a USD 140.00 target for Kymera Therapeutics stock

    Raymond James initiated coverage of Kymera Therapeutics (KYMR) with an Outperform rating and a $140.00 price target on October 8, 2026. This follows Citi raising its target to $150.00 from $135.00 on October 5, 2026...

    ad-hoc-news.de•10/13/26•Bullish

    Understanding Momentum Shifts in (KYMR)

    Kymera Therapeutics Inc. (KYMR) is experiencing a mid-channel oscillation pattern with positive near-term sentiment that may erode a mid-term weak bias within a long-term strength context. AI models have generated three...

    Stock Traders Daily•10/13/26•Neutral

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

    Purcell & Lefkowitz LLP has initiated a shareholder investigation into Kymera Therapeutics, Inc. (NASDAQ: KYMR) to determine if the company's directors breached their fiduciary duties through recent corporate actions....

    PR Newswire•10/12/26•Bearish

    Kymera Therapeutics Initiated at Outperform by Raymond James

    Raymond James has initiated coverage on Kymera Therapeutics (NASDAQ: KYMR) with an "Outperform" rating. This new rating suggests that the firm believes Kymera's stock will perform better than the average market...

    Moomoo•10/10/26•Bullish

    KYMR Valuation and Fair Value

    P/E
    -33.0x
    P/FCF
    -44.1x
    P/B
    6.9x
    See GNG's fair value

    KYMR Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -116.3%
    Net margin
    -285.3%
    ROE
    -24.1%
    FCF margin
    -226.6%
    FCF yield
    -2.3%

    KYMR Competitors

    CompanyTicker
    Cytokinetics IncCYTK
    Caris Life Sciences, Inc. Common StockCAI
    Protagonist Therapeutics IncPTGX
    Hinge Health, Inc.HNGE
    Insulet CorporationPODD
    Bruker CorporationBRKR
    Qiagen NVQGEN
    TG Therapeutics IncTGTX

    Sector: Healthcare

    KYMR Analyst Ratings

    Consensus
    Buy
    Analysts
    23
    Strong Buy
    4
    Buy
    17
    Hold
    2
    Sell
    0
    Strong Sell
    0

    KYMR Bull Case vs Bear Case

    Bull case

    • KYMR grew quarterly revenue 466.4% year over year.
    • 91.3% of KYMR's analyst ratings are Buy or Strong Buy.

    Bear case

    • KYMR has a -285.3% net profit margin.

    KYMR Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -5.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.26
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 11 down

    Frequently Asked Questions About KYMR

    Does KYMR pay dividends?

    Kymera Therapeutics Inc (KYMR) does not currently pay a regular dividend.

    What is KYMR's market cap?

    Kymera Therapeutics Inc (KYMR) has a market capitalization of $8.79B with a current stock price of $106.83.

    Related stocks

    Sector: Healthcare

    All stocks starting with K

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In